PacificGMP To Manufacture Fusion Protein For ArmaGen

ArmaGen Technologies has selected PacificGMP to produce its proprietary protein for a phase 1 clinical trial. Under the agreement, PacificGMP will use a perfusion process to produce the antibody fusion protein, AGT-190, under cGMP (current good manufacturing practices) standards. Additionally, PacificGMP is expected to perform cGMP cell bank development.

Leigh Pierce, president and CSO of PacificGMP, said: “We are delighted to have been selected by ArmaGen to produce their human clinical trial material. ArmaGen’s technology shows progress in a vital area of therapeutic development. We at PacificGMP are excited to be an important part of ArmaGen’s team for this project.”

William Pardridge, chairman of ArmaGen, said: “PacificGMP brings considerable expertise in GMP manufacturing and in perfusion bioprocessing. We are pleased to have PacificGMP manufacture AGT-190 and generate our Master Cell Bank, to support our stroke and Parkinson’s disease clinical program.”